证券代码：600572 证券简称：康恩贝 公告编号：临 2024-075 浙江康恩贝制药股份有限公司 关于注销2022年股票期权激励计划首次授予股票期权中 部分股票期权的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称：公司、本公司）于 2024 年 11 月 6 日召开十一届董事会第四次（临时）会议、十一届监事会第四次（临时）会 议审议通过《关于注销 2022 年股票期权激励计划首次授予股票期权中部分股票 期权的议案》。根据中国证监会《上市公司股权激励管理办法》、《浙江康恩贝 制药股份有限公司 2022 年股票期权激励计划（草案）》（以下简称：《激励草 案》）的相关规定以及公司 2022 年第二次临时股东大会有关决议的授权，鉴于 截至本公告日，公司 2022 年股票期权激励计划（以下简称：本次激励计划）首 次授予股票期权的激励对象中已有人员因离职、任职变化等原因不再具备激励对 象资格和行权条件，以及根据第一个考核年度激励对象个人层面绩效考核结果 （不能 100%行权的情形），董事会、 ...

浙江康恩贝制药股份有限公司董事会 对激励及激励数额的历次调整情况的说明 经 2022年 9 月 15 日召开的浙江康恩贝制药股份有限(以下简称:公司)十 届董事会第二十二次(临时)会议和十届监事会第十三次(临时)会议审议通过, 并提交于 2022年 10 月 26 日召开的公司 2022年第二次临时股东大会批准通过, 同意公司 2022年股票期权激励计划(以下简称:本次激励计划),向激励对象授 予 7,000万份股票期权。 2022年 11月 10日,经公司十届董事会第二十五次(临时)会议和十届监 事会第十五次(临时)会议审议通过,同意以 2022年 11月 10 日为本次激励计 划首次授予日,向符合条件的 537 名激励对象授予 6,247.5 万份股票期权,首次 授予的股票期权行权价格为 4.13元/股。2022年 11月 28 日,公司在中国证券 登记结算有限责任公司上海分公司(以下简称:中登公司)完成首次授予的股票 期权登记工作。 2023 年 10月 25 目,经公司十届董事会第三十三次(临时)会议和十届监 事会第二十次(临时)会议审议通过,同意以 2023年 10 月 25 日为本次激励计 划预留 ...

证券代码：600572 证券简称：康恩贝 公告编号：临 2024-074 浙江康恩贝制药股份有限公司 第十一届监事会第四次（临时）会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称：公司）第十一届监事会第四次（临 时）会议于 2024 年 11 月 6 日以通讯方式召开。会议通知于 2024 年 11 月 4 日以书面、 传真、电子邮件方式送达各监事。会议应参加审议表决监事 3 人，实际参加审议表决 监事 3 人。会议的召开符合《公司法》、《公司章程》的规定。 会议审议了有关议案，经书面表决通过决议如下： 一、审议通过《关于注销 2022 年股票期权激励计划首次授予股票期权中部分股 票期权的议案》。表决情况：同意 3 票，反对 0 票，弃权 0 票。 经核查，监事会认为：鉴于公司 2022 年股票期权激励计划首次授予股票期权的 激励对象中已有 49 名人员因离职、任职变化等原因不再具备激励对象资格和行权条 件，涉及已获授但尚未获准行权的股票期权 651.8 万份需由公司注销；以及 ...

Investment Rating - The report maintains a "Recommend" rating for Kangmei Pharmaceutical (600572) with a target price of 6.4 RMB, compared to the current price of 4.75 RMB [1] Core Views - The company's revenue and net profit declined in the first three quarters of 2024, primarily due to the normalization of demand and a decrease in sales of core products [1] - The traditional Chinese medicine (TCM) segment experienced a year-on-year decline due to a high base effect, while the specialty health consumer goods business performed well [1] - The company has optimized its expense structure and deepened R&D innovation, with several new TCM drugs submitted for approval or entering clinical trials [1] - The board of directors completed its transition in August 2024, aiming to accelerate internal growth and external expansion under the "One Platform, Two Leaders" strategy [1] Financial Performance - In Q3 2024, the company's TCM segment revenue was 24.9 billion RMB, down 11.4% YoY, while specialty chemical drugs revenue was 18.5 billion RMB, up 9.9% YoY [1] - The company's gross margin and R&D expense ratio improved by -6.2pct and +0.7pct respectively in Q3 2024 [1] - The report forecasts 2024-2026 revenue of 7.2 billion, 8.6 billion, and 10.2 billion RMB, with YoY growth rates of 22%, 15%, and 13% respectively [1] Strategic Developments - The company has submitted applications for new TCM drugs, including Linggui Zhugan Granules, and obtained clinical trial approvals for Qinghouyan Buccal Tablets and Hedera Helix Leaf Extract [1] - The new leadership team is focused on mixed-ownership reform to drive internal growth and external expansion [1] Industry Context - The report highlights the impact of healthcare reform and consumer downgrading on the pharmaceutical industry [1] - The company's performance is analyzed in the context of the broader TCM and health consumer goods markets [1]

Investment Rating - The report maintains a "Buy" rating for the company [2][4][11] Core Views - The company reported a revenue of 4.913 billion yuan for the first three quarters of 2024, a year-on-year decrease of 5.23%, and a net profit attributable to shareholders of 518 million yuan, down 16.81% year-on-year [2] - In Q3 2024, the company achieved a revenue of 1.465 billion yuan, representing a year-on-year growth of 3.16%, and a net profit of 136 million yuan, up 27.22% year-on-year, indicating a recovery in performance [2] - The decline in revenue for the first three quarters is attributed to high base effects from the previous year, particularly in gastrointestinal and respiratory medications, while increased R&D investment has also impacted profits [2] - The company is experiencing short-term pressure on traditional Chinese medicine revenues, but specialty chemical drugs and health consumer products are showing stable growth [2] - R&D expenses for the first three quarters of 2024 were 208 million yuan, reflecting a proactive approach in drug development, which is expected to drive long-term growth [2] Financial Summary - The company forecasts revenues of 7.244 billion yuan, 7.994 billion yuan, and 8.731 billion yuan for 2024, 2025, and 2026 respectively, with net profits of 730 million yuan, 841 million yuan, and 958 million yuan for the same years [2][3] - The expected EPS for 2024, 2025, and 2026 is 0.28 yuan, 0.33 yuan, and 0.37 yuan respectively, with corresponding P/E ratios of 17x, 15x, and 13x [2][3] - The company’s revenue growth is projected to be 7.59%, 10.37%, and 9.21% for 2024, 2025, and 2026 respectively, while net profit growth is expected to be 23.44%, 15.19%, and 13.95% for the same years [3][10]

Financial Performance - In Q3 2024, the company achieved revenue of CNY 1,464,554,938.58, representing a year-on-year increase of 3.16%[4] - For the first nine months of 2024, the company reported total revenue of CNY 4,913,007,257.68, a decrease of 5.23% compared to the same period last year[4] - The net profit attributable to shareholders in Q3 2024 was CNY 136,258,940.26, an increase of 27.22% year-on-year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses for the first nine months of 2024 was CNY 424,242,014.21, down 16.84% year-on-year[5] - Total operating revenue for the first three quarters of 2024 was CNY 4,913,007,257.68, a decrease of 5.2% compared to CNY 5,184,266,884.99 in the same period of 2023[21] - Operating profit for the first three quarters of 2024 was CNY 655,291,755.35, down 18.6% from CNY 805,821,869.27 in the first three quarters of 2023[21] - Net profit attributable to shareholders of the parent company for the first three quarters of 2024 was CNY 518,457,602.54, a decrease of 16.9% compared to CNY 623,237,394.18 in the same period of 2023[22] - The company reported a comprehensive income total of CNY 546,265,073.60 for the first three quarters of 2024, compared to CNY 699,887,141.20 in the same period of 2023[22] Cash Flow and Assets - The company’s cash flow from operating activities for the first nine months of 2024 decreased by 30.37% year-on-year, totaling CNY 458,455,069.75[2] - The net cash flow from operating activities decreased by 30.37% compared to the same period last year, primarily due to reduced cash receipts from sales[8] - The net cash flow from operating activities for Q3 2024 was CNY 458,455,069.75, a decrease of 30.4% compared to CNY 658,417,306.12 in Q3 2023[24] - The company reported a decrease in cash inflow from operating activities, totaling CNY 4,887,720,514.64, down from CNY 5,150,063,148.68 in Q3 2023[24] - Cash and cash equivalents decreased by 68.75% due to the payment of dividends for the year 2023[8] - As of September 30, 2024, the company's cash and cash equivalents decreased to approximately ¥803.16 million from ¥2.57 billion at the end of 2023, representing a decline of about 68.8%[16] - The company's cash and cash equivalents at the end of Q3 2024 were CNY 574,423,644.68, down from CNY 2,140,028,244.30 at the end of Q3 2023[25] - The total current assets decreased to approximately ¥4.35 billion from ¥5.78 billion, a decline of about 24.8%[16] - The company's total assets decreased to approximately ¥9.75 billion from ¥11.24 billion, a reduction of about 13.2%[17] Liabilities and Equity - The total liabilities decreased to CNY 2,994,352,739.40 in Q3 2024 from CNY 3,888,598,821.58 in Q3 2023, reflecting a reduction of 23.0%[21] - The total current liabilities decreased to approximately ¥2.46 billion from ¥3.17 billion, a reduction of about 22.4%[17] - The total equity attributable to shareholders of the parent company was CNY 6,654,671,621.88 in Q3 2024, down 5.5% from CNY 7,041,063,708.95 in Q3 2023[21] - The total equity decreased to CNY 5,844,825,233.95 from CNY 6,058,104,268.30 year-over-year[29] Research and Development - The company’s R&D expenses increased by approximately CNY 44,000,000 compared to the same period last year, impacting operating profit[5] - Research and development expenses increased to CNY 208,220,816.80 in the first three quarters of 2024, up 26.7% from CNY 164,334,399.78 in the same period of 2023[21] - Research and development expenses decreased to ¥31,681,343.09 in 2024 from ¥34,068,733.41 in 2023, showing a reduction of approximately 7.0%[30] Governance Changes - The company completed the election of the 11th Board of Directors and Supervisory Board on August 16, 2024, indicating a change in governance structure[14] - The company has made changes to its legal representative, with the new representative being the current chairman, Jiang Yi, as of August 21, 2024[14] Other Financial Metrics - The diluted earnings per share for Q3 2024 was CNY 0.035, a decrease of 14.63% compared to the same period last year[3] - Basic earnings per share for the first three quarters of 2024 were CNY 0.205, down from CNY 0.243 in the same period of 2023[22] - The company reported a decrease in financial expenses, with interest expenses falling to ¥33,375,668.34 in 2024 from ¥44,545,931.87 in 2023, a reduction of about 25.1%[30] - Investment income for the first three quarters of 2024 was ¥599,129,728.38, down from ¥1,014,996,916.07 in 2023, indicating a decline of approximately 41.0%[30]

证券简称：康恩贝 证券代码：600572 公告编号：2024-071 浙江康恩贝制药股份有限公司 关于 ZY13 提取物及片获得药物临床试验批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并 对其内容的真实性、准确性和完整性承担法律责任。 近日，浙江康恩贝制药股份有限公司（以下简称：公司、本公司）收到国家药品 监督管理局（以下简称：国家药监局）核准签发的 ZY13 提取物及片的《药物临床试验 批准通知书》。现将有关情况公告如下： 一、药物临床试验批准通知书的主要内容 药物名称：ZY13 提取物、ZY13 片（以下简称：本品） 通知书编号：2024LP02333、2024LP02334 制剂剂型：片剂 申请适应症：阴虚火旺所致的年龄相关性黄斑变性 注册分类：中药 1.2 类 申请事项：境内生产药品注册临床试验 截至本公告日，国内仅本公司进行 ZY13 提取物及片的中药 1.2 类的申报临床试 验。 （三）市场情况 申请人：浙江康恩贝制药股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，2024 年 7 月 26 日受理的 ZY13 片和 ...

证券简称：康恩贝 证券代码：600572 编号：临 2024—070 浙江康恩贝制药股份有限公司 关于 2024 年半年度业绩说明会召开情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 浙江康恩贝制药股份有限公司（以下简称：公司、本公司、康恩贝）2024 年半年 度业绩说明会于 2024 年 9 月 20 日下午 2:00-3:00 在上海证券交易所上证路演中心 （http://roadshow.sseinfo.com）采用网络平台文字互动的方式召开。公司总裁罗 国良先生，副总裁、财务总监谌明先生，副总裁、董事会秘书金祖成先生，独立董事 邱保印先生出席了本次网上业绩说明会。公司管理层就公司 2024 年半年度的经营成 果及财务指标的具体情况与投资者进行了互动交流与沟通，在信息披露允许的范围内 就投资者普遍关注的问题进行了回答。部分投资者已于 2024 年 9 月 19 日前将相关问 题通过电子邮件的形式发送至公司联系人邮箱，公司在本次说明会对有关问题也进行 了回答。有关说明会内容详见附件《浙江康恩贝制药股份有限公司关 ...

股票简称：康恩贝 证券代码：600572 编号：临 2024－069 浙江康恩贝制药股份有限公司 关于召开 2024 年半年度业绩说明会 暨问题征集的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏， 并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●会议召开时间：2024年9月20日（周五）下午2:00-3:00 ●会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com） ●会议召开方式：上证路演中心网络文字互动 ●投资者可于 2024 年 9 月 11 日至 9 月 19 日 16：00 前登录上证路演中心网站首页点击"提 问预征集"栏目或通过公司邮箱 wangyang@conbapharm.com 进行提问。公司将在业绩说明会上 对投资者普遍关注的问题进行回答。 浙江康恩贝制药股份有限公司（以下简称：公司）于 2024 年 8 月 24 日在上海 证券交易所网站 www.sse.com.cn 发布了公司 2024 年半年度报告，为进一步加强与 投资者的沟通交流，使广大投资者能更加深入、全面地了解公司情况 ...

规格：35mg 证券代码：600572 证券简称：康恩贝 公告编号：2024-068 浙江康恩贝制药股份有限公司 关于麝香通心滴丸获批国家中药保护品种 延长保护期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，国家药品监督管理局（以下简称：国家药监局）网站发布《关于中药保 护品种的公告（延长保护期第 16 号）（2024 年第 105 号）》，批准对浙江康恩贝制 药股份有限公司（以下简称：公司、本公司）全资子公司内蒙古康恩贝药业有限 公司圣龙分公司（以下简称：内蒙古康恩贝）生产的"至心砃"麝香通心滴丸继 续给予国家中药保护品种 2 级保护。现将相关情况公告如下： 一、药品基本信息 药品名称：麝香通心滴丸 剂型：丸剂 "至心砃"麝香通心滴丸为国内中药独家品种，于 2008 年获批上市，2010 年 曾经获批为国家保密品种（已到期），2017 年获批为国家中药二级保护品种，保护 期为 7 年。本次为该药品获批国家中药二级保护品种到期后的延保，保护期延长 1 功能主治：芳香益气通脉，活血化瘀止痛。用于冠心病稳定型劳累性 ...